^
Association details:
| Biomarker: | Chr inv(3)t(3;3) + MECOM overexpression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + tegavivint (BC2059) (β-catenin inhibitor, Wnt signalling pathway inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
204 Preclinical Efficacy of Novel Drug Combination Against AML with 3q26 Lesions and EVI1 Overexpression
Published date:
11/03/2022
Excerpt:
...we interrogated the pre-clinical efficacy of pan-BET inhibitor OTX015 and/or tegavivint (TV) against AML cells with inv(3)/t(3;3) and overexpression of EVI1....These findings highlight the promising pre-clinical efficacy of novel combinations of TV and BET protein or venetoclax against AML models harboring 3q26 lesions and EVI1 overexpression.
DOI:
https://doi.org/10.1182/blood-2022-170715
